Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies

BMC Systems Biology

Volumn 6, Issue , 2012, Pages

  Ben Hamo, Rotem ^a   Efroni, Sol ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLATELET DERIVED GROWTH FACTOR;

ALGORITHM; ARTICLE; BIOLOGY; COPY NUMBER VARIATION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC DATABASE; GENETICS; HUMAN; METABOLISM; METHODOLOGY; OVARY TUMOR; PHYSIOLOGY; SIGNAL TRANSDUCTION; SURVIVAL; SYSTEMS BIOLOGY;

ALGORITHMS; BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; OVARIAN NEOPLASMS; PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; SYSTEMS BIOLOGY;

EID: 84855593872     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-6-3     Document Type: Article

References (62)

1. The-Cancer-Genome-Atlas-Research-Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061-1068. The-Cancer-Genome-Atlas-Research-Network.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
3. Ahluwalia A, Yan P, Hurteau JA, Bigsby RM, Jung SH, Huang TH, Nephew KP. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol 2001, 82(2):261-268.
4. Bardos A. Treatment of ovarian cancer. 2004,
5. Swanton C, Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer 2009, 100(10):1517-1522.
6. Molina F, Dehmer M, Perco P, Graber A, Girolami M, Spasovski G, Schanstra JP, Vlahou A. Systems biology: opening new avenues in clinical research. Nephrol Dial Transplant 25(4):1015-1018.
7. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008, 452(7187):564-570.
8. Azuaje F. What does systems biology mean for biomarker discovery?. Expert Opinion on Medical Diagnostics 2010, 4:1-10.
9. Razin A. CpG methylation, chromatin structure and gene silencing - a three-way connection. Embo Journal 1998, 17(17):4905-4908.
10. Bibikova M, Lin ZW, Zhou LX, Chudin E, Garcia EW, Wu B, Doucet D, Thomas NJ, Wang YH, Vollmer E, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Research 2006, 16(3):383-393.
11. Bestor TH. Methylation meets acetylation.
12. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002, 21(35):5427-5440.
13. Pinkel D, Seagraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genetics 1998, 20(2):207-211.
14. Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, et al. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res 2009, 15(7):2448-2455.
15. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007, 25(5):517-525.
16. Yasrebi H, Sperisen P, Praz V, Bucher P. Can survival prediction be improved by merging gene expression data sets?. PLoS One 2009, 4(10):e7431.
17. Xu JZ, Wong CW. Hunting for robust gene signature from cancer profiling data: sources of variability, different interpretations, and recent methodological developments. Cancer Lett 296(1):9-16.
18. Kim SY. Effects of sample size on robustness and prediction accuracy of a prognostic gene signature. BMC Bioinformatics 2009, 10:147.
19. Field JK, Spandidos DA, Stell PM, Vaughan ED, Evan GI, Moore JP. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989, 4(12):1463-1468.
20. Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, Schroder T, Bergmann M, Wilken B, Probst-Cousin S, Hernaiz-Driever P, et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 2000, 89(5):395-402.
21. Chang CC, Kampalath B, Schultz C, Bunyi-Teopengco E, Logan B, Eshoa C, Dincer AP, Perkins SL. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med 2003, 127(2):208-212.
22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-15550.
23. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of Gene Expression Data Using BRB-Array Tools. Cancer Inform 2007, 3:11-17.
24. Xu X, Zhao Y, Simon R. Gene Set Expression Comparison kit for BRB-ArrayTools. Bioinformatics 2008, 24(1):137-139.
25. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004, 20(1):93-99.
26. Efroni S, Schaefer CF, Buetow KH. Identification of key processes underlying cancer phenotypes using biologic pathway analysis. PLoS ONE 2007, 2:e425.
27. Greenblum SI, Efroni S, Schaefer CF, Buetow KH. The PathOlogist: an automated tool for pathway-centric analysis. Bmc Bioinformatics 12:133.
28. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH. PID: the Pathway Interaction Database. Nucleic Acids Res 2009, 37(Database issue):D674-679.
29. Efroni S, Ben-Hamo R, Edmonson M, Greenblum S, Schaefer CF, Buetow KH. Detecting cancer gene networks characterized by recurrent genomic alterations in a population. PLoS One 6(1):e14437.
30. Dagostin R. Omnibus Test of Normality for Moderate and Large Size Samples. Biometrika 1971, 58(2):341-&.
31. Potter DM. Omnibus permutation tests of the association of an ensemble of genetic markers with disease in case-control studies. Genetic Epidemiology 2006, 30(5):438-446.
32. Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, Trigg NJ, Rivera BK, Kalai T, Hideg K, et al. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol Cancer Ther 9(5):1169-1179.
33. Verma A, Kambhampati S, Parmar S, Platanias LC. Jak family of kinases in cancer. Cancer Metastasis Rev 2003, 22(4):423-434.
34. Keshamouni VG, Mattingly RR, Reddy KB. Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. J Biol Chem 2002, 277(25):22558-22565.
35. Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 1997, 90(5):859-869.
36. Angel P, Hattori K, Smeal T, Karin M. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 1988, 55(5):875-885.
37. Hattori K, Angel P, Le Beau MM, Karin M. Structure and chromosomal localization of the functional intronless human JUN protooncogene. Proc Natl Acad Sci USA 1988, 85(23):9148-9152.
38. Hernandez P, Sole X, Valls J, Moreno V, Capella G, Urruticoechea A, Pujana MA. Integrative analysis of a cancer somatic mutome. Mol Cancer 2007, 6:13.
39. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004, 23(28):4921-4929.
40. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005, 16(6):601-607.
41. Uhlmann S, Zhang JD, Schwager A, Mannsperger H, Riazalhosseini Y, Burmester S, Ward A, Korf U, Wiemann S, Sahin O. miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene 29(30):4297-4306.
42. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22(10):1276-1312.
43. Jordan Schmitt DM. Platelet-Derived Growth Factor Pathway Inhibitors in Ovarian Cancer. Clinical Ovarian Cancer 2008, 1(2):120-126.
44. Schmitt J, Matei D. Targeting angiogenesis in ovarian cancer. Cancer Treat Rev
45. Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, Banerjee S, Sarkar FH. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta 1806(1):122-130.
46. Ries LA. Ovarian cancer. Survival and treatment differences by age. Cancer 1993, 71(2 Suppl):524-529.
47. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994, 170(4):974-979. discussion 979-980.
48. Bakin AV, Curran T. Role of DNA 5-methylcytosine transferase in cell transformation by fos. Science 1999, 283(5400):387-390.
49. Hu E, Mueller E, Oliviero S, Papaioannou VE, Johnson R, Spiegelman BM. Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes. EMBO J 1994, 13(13):3094-3103.
50. Mahner S, Baasch C, Schwarz J, Hein S, Wolber L, Janicke F, Milde-Langosch K. C- Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 2008, 99(8):1269-1275.
51. Hein S, Mahner S, Kanowski C, Loning T, Janicke F, Milde-Langosch K. Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines. Oncol Rep 2009, 22(1):177-183.
52. Chen TK, Smith LM, Gebhardt DK, Birrer MJ, Brown PH. Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinog 1996, 15(3):215-226.
53. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609-615.
54. Lee E, Chuang HY, Kim JW, Ideker T, Lee D. Inferring pathway activity toward precise disease classification. PLoS Comput Biol 2008, 4(11):e1000217.
55. Lee K, Chuang HY, Beyer A, Sung MK, Huh WK, Lee B, Ideker T. Protein networks markedly improve prediction of subcellular localization in multiple eukaryotic species. Nucleic Acids Res 2008, 36(20):e136.
56. Ammerpohl O, Martin-Subero JI, Richter J, Vater I, Siebert R. Hunting for the 5th base: Techniques for analyzing DNA methylation. Biochimica Et Biophysica Acta-General Subjects 2009, 1790(9):847-862.
57. Coe BP, Ylstra B, Carvalho B, Meijer GA, MacAulay C, Lam WL. Resolving the resolution of array CGH. Genomics 2007, 89(5):647-653.
58. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, Choong DY, Campbell IG. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 2007, 13(16):4731-4739.
59. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, et al. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS One 5(9).
60. Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z. High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics 2009, 2:21.
61. Efroni S, Carmel L, Schaefer CG, Buetow KH. Superposition of transcriptional behaviors determines gene state. PLoS ONE 2008, 3(8):e2901.
62. SPSS for Windows Chicago: SPSS Inc. Rel. 13.0.0. 2000, SPSS for Windows.